Eli Lilly Plans $3 Billion China Investment to Expand Weight-Loss Drug Production
Eli Lilly announced plans to invest $3 billion in China over the next decade, aiming to expand manufacturing capacity for its experimental diabetes and obesity drug, orforglipron. The investment will support production
